AUDUBON, PA & REDWOOD CITY, CA — Globus Medical (NYSE: GMED) has announced a definitive agreement to acquire all shares of Nevro Corp. (NYSE: NVRO) in an all-cash transaction worth approximately $250 million. Shareholders of Nevro will receive $5.85 per share, a 27% premium to the 90-day volume-weighted average price and a 38% premium to the 30-day VWAP.
Both companies’ boards of directors unanimously approved the deal, which positions Globus Medical to expand into the pain management market while harnessing Nevro’s highly regarded neuromodulation technology. The transaction is expected to close by the end of the second quarter of 2025, subject to regulatory and shareholder approvals.
“This transaction furthers our mission to become the preeminent musculoskeletal technology company in the world,” said Dan Scavilla, President and CEO of Globus Medical. “Our size and operational capabilities will accelerate market penetration of Nevro’s technology and bring clinically superior relief to patients suffering from chronic pain.”
Nevro CEO and President Kevin Thornal stated, “We are thrilled to join Globus Medical, as this will allow us to reach more patients globally with innovative products that significantly reduce the burden of chronic pain.”
Strategic and Financial Outlook
Globus Medical projects 2025 stand-alone net sales between $2.66 billion and $2.69 billion. If the acquisition is finalized as planned, combined net sales are expected to reach $2.80 billion to $2.90 billion. Globus forecasts the transaction will be accretive to earnings within its second year of operation.
Nevro’s preliminary 2024 revenue is estimated at $408 million to $409 million, while Globus expects 2024 net sales of $2.52 billion, a 60.6% increase over the prior year.
Broader Market Implications
The acquisition aligns with Globus Medical’s strategy to extend its influence through innovative and diversified solutions in both musculoskeletal and pain management markets. With Nevro’s advanced technology and Globus Medical’s operational strength, the partnership seeks to redefine patient care across these sectors.
Both companies anticipate the merger will drive meaningful growth, enhance financial performance, and deliver improved therapeutic solutions, leaving a lasting impact on the global medical device landscape.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.